Andrew Storaska works with clients to develop durable patent protection and build broad IP portfolios for U.S. and worldwide coverage. He also works with clients to identify ways to enhance the scope and strength of their existing IP protection.

Andrew also plays a vital strategic role in patent protection for clients. On an ongoing basis, he assesses scientific literature, patents, and patent application documents in a variety of technology fields in order to assist with IP diligence for business development, licensing, and acquisitions. In concert with this, he also works with clients to review IP landscapes to identify third-party patents and patent applications for competitive intelligence and business strategy. He also assists clients with post-grant proceedings before the U.S. Patent Office’s Patent Trial and Appeal Board (PTAB).

He works with scientists, engineers, and inventors to draft and prepare patent applications and manage the prosecution of patent applications through the USPTO. As part of broader global patent portfolio management, he coordinates worldwide prosecution with foreign associates so clients can attain strong patent protection across the globe.

A few examples of Andrew’s work: he will assist clients in responding to post-grant validity attacks on their patents. He’ll assist in reviewing and clearing the patent landscape so clients can bring their own inventions to markets with surety. This includes assisting clients with employing post-grant patent review procedures.

His clients include pharmaceutical, biotechnology, chemical companies, device manufacturers, and companies involved in building and industrial applications.

His capabilities are augmented by extensive experience as a working scientist. Following receipt of a B.S. in cell biology and molecular genetics and a doctorate in Pharmacology, he conducted research as a post-doctoral fellow investigating the molecular connections between oncogenic signaling pathways and stem cell transcriptional networks in brain tumor stem cells. As a part of this work he evaluated FDA-approved small molecule drugs for new therapeutic applications. He also managed several small molecule screening projects, and collaborated with medicinal chemists on chemical optimization steps through early stages of pre-clinical small molecule development. Andrew also has extensive experience with protein engineering, protein purification procedures, and biochemical assay design. Through his work he has authored numerous published scientific articles.

His scientific knowledge allows him to understand and communicate effectively across a wide array of technologies, enabling him to assist clients to meet their business goals, develop effective strategies, and navigate through the legal landscape.

*Not admitted to the D.C. Bar



Co-author, "Modeling patient-derived glioblastoma with cerebral organoids." Cell reports 26, no. 12 (2019): 3203-3211.

Co-author, “A Core Regulatory Circuit in Glioblastoma Stem Cells Links MAPK Activation to a Transcriptional Program of Neural Stem Cell Identity.” Scientific Reports 7, (2017) Article number: 43605.

Co-author, “Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors.” ACS Chem Neuroscience 6, (2015) 911–919.

Co-author, “Redox Modification of Nuclear Actin by MICAL-2 Regulates SRF Signaling.” Cell 15, (2014) 563-76.

Storaska, A. J., et al. “Conformational Dynamics of a Regulator of G-Protein Signaling Protein Reveals a Mechanism of Allosteric Inhibition by a Small Molecule.” ACS Chemical Biology 12, (2013) 2778-84. (Co-first author).

Storaska, A. J., and Neubig, R. R. “NMR methods for detection of small molecule binding to RGS4.” Methods in Enzymology 522, (2013) 133-152.

Storaska, A. J., et al. “Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay.” Cellular Signaling 25, (2013) 2848-2855.

Co-author, “Perturbing the ubiquitin pathway reveals how mitosis is hijacked to denucleate and regulate cell proliferation and differentiation in vivo.” PloS One 5, (2010) e13331.

Co-author, “Structure of the s5a:k48-linked diubiquitin complex and its interactions with rpn13.” Molecular Cell 35, (2009) 280-290.


J.D., George Mason University Antonin Scalia Law School

Ph.D., Pharmacology, University of Michigan, Ann Arbor

B.S., Cell Biology & Molecular Genetics, University of Maryland, College Park

Bar & Court Admissions

Bar Admissions

  • U.S. Patent and Trademark Office
Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.